广州中医药大学学报2026，Vol.43Issue(1)：142-148,7.DOI:10.13359/j.cnki.gzxbtcm.2026.01.020
浮针联合西药治疗肝郁气滞证腹泻型肠易激综合征的临床观察
Clinical Observation of Fu's Subcutaneous Needling Combined with Western Medicine for Diarrhea-Predominant Irritable Bowel Syndrome with Liver Depression and Qi Stagnation Syndrome
摘要
Abstract
Objective To evaluate the clinical efficacy of Fu's Subcutaneous Needling(FSN)combined with conventional western medicine in treating diarrhea-predominant irritable bowel syndrome(IBS-D)with liver depression and qi stagnation syndrome.Methods A total of 100 patients diagnosed with IBS-D(liver depression and qi stagnation type)were enrolled from the wards and Outpatient Departments of Xingtai Central Hospital between January 2021 and August 2024.They were randomly divided into an observation group and a control group(n=50 each)using a random number table.The control group received health education combined with conventional western medicine,while the observation group received additional Fu's Subcutaneous Needling therapy based on the control group's treatment.The treatment duration was 4 weeks for both groups.After one month of treatment,clinical efficacy was evaluated.Changes in the Irritable Bowel Syndrome-Severity Scoring System(IBS-SSS),traditional Chinese medicine(TCM)syndrome scores,and Irritable Bowel Syndrome-Quality of Life(IBS-QOL)scores were observed before and after treatment.Levels of inflammatory factors[interleukin-8(IL-8),high-sensitivity C-reactive protein(hs-CRP),interferon-γ(IFN-γ)],gastrointestinal hormones[motilin(MTL),vasoactive intestinal peptide(VIP),5-hydroxytryptamine(5-HT)],and gut microbiota composition were compared between the two groups before and after treatment.Safety and adverse reactions were also assessed.Results(1)During the study,one patient was excluded from the control group and two from the observation group.Finally,49 patients in the control group and 48 in the observation group were included in the efficacy analysis.(2)After treatment,both groups showed significant improvements in IBS-SSS scores,TCM syndrome scores,and IBS-QOL scores(P＜0.05).The observation group demonstrated significantly greater improvements in these scores compared to the control group,with statistically significant difference(P＜0.05).(3)After treatment,both groups showed significant improvements in IL-8,hs-CRP,and IFN-γ levels(P＜0.05),with the observation group exhibiting significantly greater improvements than the control group,with statistically significant difference(P＜0.05).(4)After treatment,both groups showed significant improvements in MTL,VIP,and 5-HT levels(P＜0.05),and the observation group demonstrated significantly greater improvements than the control group,with statistically significant difference(P＜0.05).(5)After treatment,both groups showed significant improvements in gut microbiota(P＜0.05),with the observation group showing significantly greater improvement than the control group,with statistically significant difference(P＜0.05).(6)The total effective rate was 95.83%(46/48)in the observation group and 81.63%(40/49)in the control group,with the observation group showing significantly superior efficacy,with statistically significant difference(P＜0.05).(7)The incidence of adverse reactions was 4.17%(2/48)in the observation group,while no significant adverse reactions occurred in the control group.The difference in the incidence of adverse reactions between the two groups was not statistically significant(P＞0.05).Conclusion Fu's Subcutaneous Needling combined with conventional western medicine significantly reduces disease severity,alleviates clinical symptoms,decreases inflammatory factor levels,regulates gastrointestinal hormones,corrects gut microbiota dysbiosis,and improves quality of life in patients with IBS-D(liver depression and qi stagnation type),demonstrating notable efficacy and a favorable safety profile.关键词
浮针/腹泻型肠易激综合征/肝郁气滞证/炎症因子/胃肠激素/肠道菌群/临床观察Key words
Fu's Subcutaneous Needling/diarrhea-predominant irritable bowel syndrome(IBS-D)/liver depression and qi stagnation syndrome/inflammatory factors/gastrointestinal hormones/gut microbiota/clinical observation分类
医药卫生引用本文复制引用
张志卓,张倩,张立涛,梁冬红..浮针联合西药治疗肝郁气滞证腹泻型肠易激综合征的临床观察[J].广州中医药大学学报,2026,43(1):142-148,7.基金项目
邢台市科技计划自筹经费项目(编号:2024ZC197) （编号:2024ZC197）
